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Abstract
Background: Mitochondrial DNA depletion syndromes (MDS) are clinically and phenotypically heterogeneous
disorders resulting from nuclear gene mutations. The affected individuals represent a notable reduction in
mitochondrial DNA (mtDNA) content, which leads to malfunction of the components of the respiratory chain. MDS
is classified according to the type of affected tissue; the most common type is hepatocerebral form, which is
attributed to mutations in nuclear genes such as DGUOK and MPV17. These two genes encode mitochondrial
proteins and play major roles in mtDNA synthesis.
Case presentation: In this investigation patients in three families affected by hepatocerebral form of MDS who
were initially diagnosed with tyrosinemia underwent full clinical evaluation. Furthermore, the causative mutations
were identified using next generation sequencing and were subsequently validated using sanger sequencing. The
effect of the mutations on the gene expression was also studied using real-time PCR. A pathogenic heterozygous
frameshift deletion mutation in DGUOK gene was identified in parents of two affected patients (c.706–707 + 2 del:
p.k236 fs) presenting with jaundice, impaired fetal growth, low-birth weight, and failure to thrive who died at the
age of 3 and 6months in family I. Moreover, a novel splice site mutation in MPV17 gene (c.461 + 1G > C) was
identified in a patient with jaundice, muscle weakness, and failure to thrive who died due to hepatic failure at the
age of 4 months. A 5-month-old infant presenting with jaundice, dark urine, poor sucking, and feeding problems
was also identified to have another novel mutation in MPV17 gene leading to stop gain mutation (c.277C > T:
p.(Gln93*)).
Conclusions: These patients had overlapping clinical features with tyrosinemia. MDS should be considered a
differential diagnosis in patients presenting with signs and symptoms of tyrosinemia.
Keywords: Mitochondrial DNA depletion syndrome, DGUOK, MPV17, Mitochondrial disorders
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Background
Mitochondrial diseases are clinically and phenotypically
heterogeneous disorders caused by defects in mitochon-
drial DNA (mtDNA) or nuclear genes encoding proteins
directly or indirectly involved in mtDNA maintenance
(respiratory subunits, assembly factors, enzymes, etc.). A
wide range of mutations has so far been reported in pa-
tients affected with mitochondrial disorders [1–5].
MDS is inherited as autosomal recessive disorder and
mainly has an early onset. It is associated with a notable
reduction in mtDNA content, which causes inappropri-
ate function of the respiratory chain components affect-
ing a specific tissue or multiple organs such as muscle,
liver, brain, and kidney [6, 7]. Regarding the affected or-
gans, MDS is classified into four categories: myopathic,
encephalomyopatic, hepatocerebral, and neurogastroin-
testinal forms. Each type results from different nuclear
genes mutations (Additional file 1: Table S1). It has been
reported that these genes have major roles in nucleotide
synthesis and replication of mtDNA and their mutations
disrupt mtDNA maintenance [8, 9].
Hepatocerebral type of MDS is the most common form
caused by mutations in the following nuclear genes:
TWNK, POLG, DGUOK, MPV17, and TFAM [2, 3, 10].
The hepatocerebral type generally occurs in infants of less
than 6months of age and usually results in death within
the first year of life, chiefly due to hepatic failure [11].
Mutations in DGUOK, encoding the mitochondrial
deoxyguanosine kinase, causes MDS type 3, an early-
onset disease belonging to hepatocerebral form. This
enzyme phosphorylates purine nucleotides to nucleotide
monophosphates and provides balanced supply of nucle-
otides necessary for mtDNA replication [12]. DGUOK is
a ubiquitously expressed gene with the highest expres-
sion in muscle, brain, liver, and lymphoid tissues [13].
The affected neonates are mostly diagnosed with
hepatic and neurological defects, lactic acidosis, and
hypoglycemia in the first few weeks of life. They present
with progressive liver disease (the most common cause
of death), low-birth weight, and neurological impair-
ments (e.g., myopathy, developmental delay, nystagmus,
and hypotonia) [14, 15].
MPV17, one of the recently discovered genes found to
be related to hepatocerebral class, is associated with MDS
type 6. It is a ubiquitously expressed gene encoding a
highly conserved protein in the inner mitochondrial mem-
brane. MDS type 6 is usually characterized by infantile- or
childhood-onset progressive hepatic disease, neurological
defects as well as metabolic manifestations such as lactic
acidosis and hypoglycemia [16–18]. However, there have
been reports of adult-onset mtDNA deletion disease due
to MPV17 mutations [19, 20]. In contrast to other forms
of MDS, neurological defects are usually milder on pres-
entation in MDS caused by mutations in MPV17 [21].
According to some investigations, the levels of tyrosine
and phenylalanine are elevated in blood or urine of those
with DGUOK and MPV17 mutations found in their
newborn screening [22, 23]. Tyrosinemia is an inborn
error of metabolism caused by impaired tyrosine
metabolism [24]. Herein, we report on the disease-
causing mutations in three families affected with hepato-




WES was carried out on whole blood samples taken
from parents of all patients to capture and enrich all
exons of protein coding genes in addition to other essen-
tial parts of the genome. Next generation sequencing
(NGS) was performed using Illumina Hiseq 2000
machine to sequence close to 100 million reads and
standard Illumina protocol for pair-end 99 nucleotide
sequencing. Basically, the test platform assayed > 95% of
the target regions with sensitivity of above 99%.
Sanger sequencing
To confirm the novel mutations, whole blood samples
were collected from healthy parents of all three families
in EDTA tubes. All probands of the affected families had
died at the time of investigation. However, we had access
to the extracted DNA sample from a daughter of family
II that was kept in hospital at − 20 °C, dry umbilical cord
that belonged to the affected son of family III, and chori-
onic villus sample (CVS) from the 7-week pregnant
mother of family I. DNA was extracted from all samples
(blood, CVS, tissue) using QIAamp DNA Minikit (Qia-
gen, Germany) according to the manufacturer’s instruc-
tions. The DNA concentration was then evaluated by
Epoch Microplate Spectrophotometer (Bio Tek Instru-
ments, USA) and stored at − 20 °C until use.
Following oligonucleotide PCR primers were utilized to
amplify the desired genome regions: DGUOK (F-Exon5: 5′
AAGACTGCATTGTAGCAG 3′ and R-Exon5: 5’CAG-
CAATATTAAACTTCTGAGT 3′), MPV17 (F-Exon4: 5′
AGTGAGGTAGAGGCCTAG3’ and R-Exon4: 5′ CTGC
ACCATAACCCTCAG 3′), MPV17 (F-Exon7: 5′ TGGT
GCAGGAATGTGCTC 3′ and R-Exon7: 5′ CTGCAG
CCTAGGTTAGAC 3′).
Sanger sequencing was then conducted in both direc-
tions on the amplified DNA segments using ABI BigDye
Terminator Cycle Sequencing kit (Applied Biosystems®,
USA).
Real-time PCR
Total RNA was isolated from whole blood sample taken
from heterozygous parents and also umbilical cord tissue
of the deceased homozygous individual in family III
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using Invitrogen TRIzol Reagent according to the com-
pany protocol. RNA concentration, purity and integrity
was then measured by Epoch Microplate Spectropho-
tometer (Bio Tek Instruments, USA). The resulting RNA
samples were used for cDNA synthesis using Fermentas
cDNA synthesis kit (Thermo Fisher Scientific, USA). We
used a Rotor-Gene Q (QIAGEN, Germany) real-time
PCR cycler by Invitrogen SYBER Green Master Mix to
evaluate any alteration in DGUOK and MPV17 gene ex-
pression of parents’ blood and umbilical cord compared
with that of a normal control. The following primer
pairs were used to assess DGUOK and MPV17 expres-
sion: DGUOK-QPCR-F: 5′ TGGGAAAGTCCACGTTT
GTGAA 3′, DGUOK-QPCR-R: 5′ AATGTGTAGGAC
CATCGTGCTG 3’and MPV17-QPCR-F: 5′ ACTACA
GCGGGATTATCCT 3′, MPV17-QPCR-R: 5′ TAACAG
CAACACATTGGAC 3′. We also used glyceraldehyde
3-phosphate dehydrogenase (GAPDH) as the reference
gene by these primer pairs: GAPDH-QPCR-F: 5′
ACAACTTTGGTATCGTGGAAGG 3′, GAPDH-QPC
R-R: 5’GCCATCACGCCACAGTTTC3’.
Differences in the relative gene expression was evalu-
ated by cycle threshold (Ct) values. We used 2-ΔΔCt
method to calculate relative expression between men-
tioned genes and GAPDH gene as the internal control.
Bioinformatics
Herein, several bioinformatics analyses were conducted
using a wide variety of software programs. BWA aligner
was used for aligning sequence reads (obtained from
WES) against human genome [25]. Genome variants
were identified by GATK [26]; then annotated using
ANNOVAR software [27]. Public databases and standard
bioinformatics software programs, such as CADD_
phred, SIFT, Polyphen, Phastcons, LRT, Mutation
Taster, and Mutation Assessor were used to evaluate the
NGS results.
I-TASSER server (https://zhanglab.ccmb.med.umich.
edu/I-TASSER/) was used to predict 3D structure of
proteins [28, 29]. Wild-type and mutant protein struc-
ture of proteins were then compared with UCSF
chimera.
Multiple sequence alignment software program was
also used to conduct comparative amino acid sequence
alignment of MPV17 and DGUOK proteins.
Family Ι: patients Ι
Patient I was a 6-month-old girl, known case of liver cir-
rhosis, who presented with dyspnea, bloody vomiting,
diarrhea, lethargy, jaundice, and dark urine. She was the
second child of non-symptomatic parents who were
first-degree cousins. The first child of the family present-
ing with similar symptoms had died at the age of 3
months. Both children had impaired fetal growth, low-
birth weight, and failure to thrive. Both were floppy and
hypotonic and developed prolonged jaundice and green-
colored stool. The first infant weighted 1700 g at birth,
had Apgar scores of 8 and 9 at the 1st and 5th min, re-
spectively. The second child weighted 2500 g with re-
spective Apgar scores of 8 and 8. Moreover, the first
infant suffered from an unspecified ophthalmologic
problem. She died at the age of 3 months due to pro-
gressive respiratory insufficiency.
On physical examination, stridor was heard over the
entire lung fields on auscultation. The abdomen was dis-
tended with mild free ascitic fluid. Her vital signs in-
cluded a heart rate of 142 beats/min, respiratory rate of
44 breaths/min, axillary temperature of 36.9 °C, and per-
ipheral blood O2 saturation of 56% on breathing the am-
bient air.
Laboratory evaluations indicated increased serum
ALT, AST, Alk-P, AFP, and total bilirubin, and pro-
longed PT and PTT (Table 1). Viral markers were nega-
tive. Immunoglobulin levels were within normal range.
Blood sample assay showed slightly decreased biotini-
dase and normal Gal-P urodyltransferase activities. Tan-
dem mass spectrometry showed elevated level of
phenylalanine, tyrosine, and methionine. Based on
Table 1 Laboratory findings in the patients showing increased Alk-P, AFP, and blood tyrosine levels in all affected individuals
Variable Patient I Patient II Patient III
AST (Reference range: < 60 U/L) 942 241 176
ALT (Reference range: < 45 U/L) 554 106 61
Alk-P (Reference range: 124–341 U/L) 1274 897 2700
AFP (Reference range: 0–97 ng/mL) 16,372 291 > 2000
Total Bilirubin (Reference range: < 1.9 mg/dL) 12.8 11.9 10.5
Direct Bilirubin (Reference range: < 0.2 mg/dL) 3.2 4.7 3.9
PT (Reference range: 10.5–11.5 s) > 60 21.8 34
PTT (Reference range: 24–36 s) 58 59 58
Blood tyrosine (Reference range: 20–100 μmol/L) 240 176 309
Blood succinylacetone (Reference range: < 5.0 mcM) < 5.0 < 5.0 < 5.0
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clinical picture, the patient was initially diagnosed as
having either tyrosinemia or galactosemia. On the third
day of admission, the patient died. The family was re-
ferred for genetic counselling to find out whether the
underlying problem was hereditary and to terminate the
current pregnancy if necessary.
NGS data analysis revealed a pathogenic heterozy-
gous frameshift deletion mutation in DGUOK gene
(DGUOK: NM_001318860:exon5:c.706_707 + 2del:
p.K236 fs) that was present in both parents. Homozy-
gous or compound heterozygous DGUOK gene muta-
tions have been reported in hepatocerebral MDS.
Sanger sequencing confirmed the heterozygous frame-
shift deletion in the parents. Therefore, the disease
might be inherited as an autosomal-recessive trait.
Sanger sequencing study of the CVS sample revealed
that the current pregnancy was a heterozygous carrier
of the mutation (Fig. 1a).
Clustal Omega multiple sequencing alignment was
used to align different functional isoforms of DGUOK
proteins. The result showed that all functional isoforms
of DGUOK protein shared the same amino acid
sequence after the position 236 (Fig. 1b). This
highlighted the vital role of these amino acids in the pro-
tein’s functions. As mentioned above, the exact position
of the observed deletion mutation was at amino acid 236
(p.K236 fs), which could be an evidence for pathogenicity
of this mutation. Mutation taster online software was
also used and predicted this variation as a disease caus-
ing variant resulting in a non-sense mediated decay at
position 239 in the mutant amino acid sequence [30].
3D structure of wild-type and mutant proteins were pre-
dicted using I-TASSER server [28, 29]. UCSF chimera
was used to compare these two structures (Fig. 1c).
Real-time PCR analysis of DGUOK mRNA expression
level revealed no significant difference between parents
(heterozygous carriers) and healthy control (Fig. 2a).
Family ΙΙ: patient ΙΙ
The second patient was a 4-month-old girl who pre-
sented with jaundice since one month prior to admis-
sion. She also had weak crying, muscle weakness, poor
sucking, and failure to thrive. Being a product of full-
term normal vaginal delivery, she had normal APGAR
score, and birth weight and head circumference. The pa-
tient had an episode of seizure when she was 12 days
old. The parents were second-degree cousins and had a
younger sibling who had died at the age of 9 months due
to an unknown metabolic disorder. The mother also re-
ported a previous abortion.
Detailed neurological examination revealed neurodeve-
lopmental delay and muscle weakness in patient II. The
“Fix and Follow test” of moving objects was abnormal.
The physical examinations were otherwise unremarkable.
Fig. 1 a Family I pedigree and sequence chromatograms. Both parents are heterozygous for the frameshift deletion mutation in DGUOK gene.
The current pregnancy was a heterozygous carrier of the mutation. The proband is marked by an asterisk. b Clustal Omega multiple sequence
alignment of all functional human encoding isoforms of DGUOK protein showing that all functional isoforms share the same amino acid
sequence after codon 236. c Three dimensional structure of DGUOK wild type and mutant proteins were predicted by I-TASSER server. UCSF
chimera was used to compare the structures. The deleted region is displayed in pink
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She had no abnormal findings on brain MRI. Diagnostic
laboratory evaluations revealed elevated serum AST, ALT,
AFP, and prolonged PT and PTT (Table 1). Tyrosine level
was also elevated. Liver biopsy was in favor of cirrhosis.
This patient was also initially diagnosed as having tyrosi-
nemia. She died of hepatic failure at the age of 4 months.
NGS results showed a novel heterozygous missense
(splice donor site) mutation in MPV17 gene (MPV17:
NM_002437:exon7:c.461 + 1G > C) in the parents.
Mutation in this gene can cause autosomal-recessive
mitochondrial DNA depletion syndrome 6 (hepatocereb-
ral type). Sanger sequencing confirmed heterozygosity
and homozygosity for the mentioned splice site donor
mutation in both parents and the patient, respectively,
indicating the autosomal-recessive inheritance pattern
for this disease (Fig. 3). According to the mutation
taster, this variant is disease causing leading to change in
the conserved splice site nucleotide. Conservation ana-
lysis of this nucleotide also revealed a Phylop score of
3.966 and a Phastcons score of 1.
Fig. 3 Family II pedigree and sequence chromatograms. Both parents are heterozygous and the affected individual is homozygous for this
mutation in MPV17 gene. The proband is marked by an asterisk
Fig. 2 Quantitative real-time PCR results. a DGUOK mRNA expression levels show no significant differences between heterozygous parents and
normal individual. b In family II, MPV17 mRNA expression reduced in heterozygous parents compared with normal control. c Real-time PCR
analysis of MPV17 gene in parents and the affected proband in family III and normal control, showing significant reduction in mRNA expression
level in the proband compared with normal control
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Analysis of MPV17 mRNA using real-time PCR on
heterozygous parents clearly indicated significant de-
creased level of MPV17 mRNA expression compared
with normal control. It can be concluded that one mu-
tated copy of MPV17 gene can affect the expression of
this gene (Fig. 2b). However, one copy of this gene is
sufficient to provide functional MPV17 protein in het-
erozygous carrier. Since we did not have RNA from the
deceased child, real-time PCR only was performed on a
heterozygous carrier. As a result, the mutation in
MPV17 gene described here can contribute to hepato-
cerebral MDS.
Family ΙΙΙ: patient ΙII
A 5-month-old boy, whose parents were first-degree
cousins, was brought to the Pediatric Neurology ward of
Namazi Hospital due to malaise, jaundice, dark urine,
poor sucking, and feeding problems. He also had neuro-
developmental delay. The patient was the second child
of a healthy couple and was a product of full-term nor-
mal vaginal delivery. He had normal APGAR scores. His
weight and head circumference were appropriate at birth
and during infancy.
He had previous history of hospital admission at the age
of 16 days for prolonged jaundice, dark urine, and leth-
argy. Moreover, his serum ferritin level, AFP, AST, ALT,
Alk-P, and total bilirubin levels were high (Table 1). All
viral markers studied were negative. Ophthalmologic and
gastrointestinal studies did not show any abnormalities.
He also had an abnormal electroencephalogram (EEG)
with epileptiform activities. Due to high serum phenyl-
alanine and tyrosine levels in PKU screening (using tan-
dem mass spectrometry), the patient was initially treated
with PKU formula and phenobarbital. He was subse-
quently discharged with close clinical follow-up. He was
apparently well until the age of 5months when he was
admitted with the primary diagnosis of tyrosinemia due to
high tyrosine level in his serum. Otherwise, the physical
examinations showed no abnormalities. Laboratory evalu-
ations revealed increased serum AST, ALT, Alk-P, AFP,
total and direct bilirubin, and tyrosine levels, and pro-
longed PT and PTT (Table 1). The patient died on the
second day of admission.
NGS analysis results on parents revealed a novel hetero-
zygous nonsense (stop gain) mutation in another region of
MPV17 gene (MPV17: NM_002437: c.277C > T:
p.(Gln93*)). Sanger sequencing revealed that both parents
were heterozygous and the proband was homozygous for
this mutation (Fig. 4a). Mutation taster predicted that this
variation is a disease causing variant. The comparative
amino acid alignment of MPV17 protein was conducted
across different animal kingdoms using multiple sequence
alignment analysis by T-Coffee Multiple Sequence
Alignment Program. The Q93 residue was highly con-
served (Fig. 4b). In addition, prediction of the 3D protein
structure using I-TASSER server [28, 29], revealed struc-
tural alterations resulting from this stop-gain mutation
(Fig. 4c).
Real-time PCR was performed on three members of
this family. mRNA expression in normal individuals was
significantly higher than that in parents and the pro-
band. It clearly demonstrated the depletion in MPV17
expression in the proband (Fig. 2c).
Discussion and conclusions
MDS is a heterogeneous disorder that results from a
reduction in mtDNA copy number. It can lead to a wide
range of clinical presentations due to insufficient synthe-
sis of the respiratory chain complexes (I, III, IV, V),
which ultimately leads to insufficient energy production
and mitochondrial dysfunction [6, 7, 31].
Hepatocerebral type of MDS often occurs in the in-
fancy and its common early symptoms include persistent
vomiting, failure to thrive, hypotonia, and hypoglycemia.
To date, numerous genes associated with MDS have
been identified. Mutations in DGUOK and MPV17,
which are involved in mtDNA maintenance, have been
reported in the hepatocerebral form of the disorder [2].
In this paper, we report on three hepatocerebral MDS
cases which resulted from mutations of DGUOK gene in
one family and MPV17 gene in two families.
DGUOK has seven exons, encoding the mitochondrial
deoxyguanosine kinase, which supplies dNTP for
mtDNA replication. Mandel, et. al., illustrated a region
on chromosome 2p13 by homozygosity mapping that in-
cluded DGUOK gene in three families with hepatocereb-
ral MDS. It was found that a nucleotide deletion (204
del A) in DGUOK segregated with the disease [31, 32].
With advancements in genetics sequencing techniques,
especially next generation sequencing, detecting these
mutations has become easier. According to The Human
Gene Mutation Database (HGMD), 57 mutations have
so far been reported in DGUOK gene—34 missense/
nonsense, 6 splicing, 9 small deletions, 5 small insertions
and 3 gross deletions. These mutations affect both the
conserved and non-conserved DGUOK amino acids [33].
Whole exome sequencing of the couple in family I il-
lustrated a deleterious heterozygous frameshift deletion
mutation in DGUOK gene in both parents. Frameshift
mutations may indirectly cause a premature termination
codon and give rise to translation reading frameshift or
sometimes altered splicing [34].
The parents of the patient in family I were carriers of
a mutation resulting in deletion of four nucleotides
(c.706–707 + 2 del AAGT) located in a splice donor site.
Sezer, et. al., reported a 2-month-old girl with deletion
mutation of DGUOK gene in this region (c.707 + 3–6
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del TAAG) that affects splicing site and causes mito-
chondrial DNA depletion syndrome [35]. Here we report
another patient with a deleterious mutation in this
region.
In this study, the heterozygous parents showed normal
DGUOK mRNA expression compared to normal con-
trol, reflecting that one mutated copy of this gene had
no effect on mRNA expression. However, in silico inves-
tigations revealed that AAGT deletion could ultimately
result in premature translation termination after codon
236, producing a truncated protein and might therefore
affect the 3D protein structure or lead to non-sense me-
diated decay at position 239 in the mutant amino acid
sequence; the wild type stop codon is located at position
278 in the amino acid sequence.
Three-dimensional protein structure of DGUOK was
identified in 2001; two domains (β-5 and α-9) were dis-
covered after position 245 [36]. Wang, et. al., showed
that the C-terminal α-helix number 9 (α-9) domain of
DGUOK has a vital role in enzyme activity as part of
Fig. 4 a Family III pedigree and sequence chromatograms. Both parents are heterozygous and the affected proband is homozygous for this stop-
gain mutation in MPV17 gene. The proband is marked by an asterisk. b Comparative amino acid alignment of MPV17 protein across different
kingdoms. The conserved glutamine residue is shown in the box. c Protein structure was predicted by I-TASSER server for 3D protein structure
prediction. The secondary structure of protein is changed as a result of the mutation. The deleted region is showed in pink
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phosphate donor binding site [37]. Therefore, it seems
that the identified frameshift deletion in DGUOK gene
could result in DGUOK deficiency and cause MDS type
3 syndrome in family I.
Patients with DGUOK deficiency would eventually
show early-onset liver failure, which is the most com-
mon symptom. However, neurological involvement may
be mild or absent [38]. Our patient had hepatomegaly
and failure to thrive and died of liver failure. It is worth
mentioning that the levels of three amino acids—phenyl-
alanine, tyrosine, and methionine—were elevated in tan-
dem mass spectrometry results of newborn screening.
The observation is associated with liver failure and can
be observed in large number of newborns affected by
multiorgan form of the disease. Elevated hepatic en-
zymes concentration in the serum, direct hyperbilirubi-
nemia, and increased gamma-glutamyltransferase levels
were also observed in the affected infants, reflecting
intrahepatic cholestasis [39].
Spinazzola, et. al., reported a new locus for hepato-
cerebral MDS on chromosome 2p21–23 by genome
wide linkage analysis. MPV17 was one of the top can-
didate genes. MPV17 mutations segregated with the
disease in all affected families [17]. The gene has
eight exons, encoding a mitochondrial inner mem-
brane protein. Although its main function is still un-
known, loss of function in this protein has been
shown to cause aberrant oxidative phosphorylation
(OXPHOS) and mtDNA depletion in MPV17 knock
out mice model [40].
MPV17 protein, which was assumed to be located
in peroxisome, has been proven to be localized in the
mitochondria [17]. So far, 37 pathogenic variants have
been reported in MPV17 genes on The Human Gene
Mutation Database (HGMD)—19 missense/nonsense
mutations, 5 splicing variants, 6 small deletions, 2
small insertions, 1 small indels and 4 gross deletions.
Most of these mutations were reported as private, ex-
cept p.Arg50Gln mutation, which is the most com-
mon form [41].
In the current study, a novel missense mutation was
identified in family II at a conserved splice donor site
(GT at the 5′ end of an intron). It causes inaccurate pat-
tern of RNA splicing that leads to exon omission (exon
skipping) or failure to splice out an intron (intron reten-
tion). Abnormal splicing may lead to a frameshift muta-
tion at the RNA level, which induces RNA degradation
or production of a truncated protein [30]. As real-time
PCR results suggested, MPV17 was significantly down-
regulated in the heterozygous parents. This could be at-
tributed to asymmetrical degradation of different spli-
cing forms resulting from the mutation or the
detrimental effect of the pathogenic variant on the re-
gions of the gene most important for its expression.
In family III, the results showed a novel nonsense mu-
tation (stop gain) in exon 4 of MPV17, which changed
the p.93Q into the stop codon. The resultant mRNA
might be targeted by a mechanism known as nonsense-
mediated decay. The Q93 residue is highly conserved
during evolution, which conveys the crucial role of glu-
tamine in this residue. Position of the stop codon in the
wild type amino acid sequence is in codon 177, while
that of the mutant one is in codon 93. Therefore, the
mutation would significantly affect the protein structure,
which was also shown using I-TASSER server for 3D
protein structure prediction. According to the Pfam
database, there is a potential transmembrane helical
structure might exist from codon 95 to 115 of the pro-
tein and an early stop codon in position 93 can thus dis-
rupt the protein structure. Analysis of mRNA expression
results showed that MPV17 was significantly down-
regulated in the proband compared with a normal
homozygous individual. On account of the evidence pre-
sented, it can be concluded that this mutation can give
rise to hepatocerebral MDS disorder.
No successful treatment has so far been found for
patients with mitochondrial hepatopathy. Researchers
have conducted investigations into the effect of various
vitamins, cofactors and respiratory substrates for the
treatment of these patients. However, none of these
interventions have been found effective. Liver transplant-
ation can only be partly effective in the absence of
neurological symptoms [9].
We found one mutation in DGUOK gene and two
novel mutations in MPV17 in patients affected by hepa-
tocerebral MDS. Due to increased serum tyrosine levels
in most of the affected individuals, MDS has overlapping
clinical features with tyrosinemia. Therefore, suspected
cases should be provided with professional genetic coun-
selling to give correct diagnosis. Moreover, physicians
should be more aware of MDS as a differential diagnosis
in patients with such overlapping symptoms. Molecular
diagnosis may be designed to help in identifying MDS
patients and families and establish accurate prenatal
diagnosis of high risk individuals.
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